London-based growth debt investor Claret Capital Partners has raised €575 million in its latest fundraising cycle, exceeding its initial €500 million target for Claret European Growth Capital Fund IV.
- Founded in 2013, Claret Capital Partners provides flexible financing to companies across the technology, life sciences, and impact sectors. The firm has raised €1.3 billion since inception and deployed more than €1.5 billion across over 210 companies.
- The latest raise comprises €440 million in Fund IV commitments and €135 million in affiliated discretionary mandates. The fund has already deployed 32% of its capital across 27 companies, including B2B payments platform Billie, pharmaceutical company Cinclus Pharma, biotech firm Inventiva, and sales intelligence platform Surfe.
- Fund IV attracted commitments from pension funds, insurers, family offices, institutional investors, and private wealth investors through an ELTIF structure. Claret has also established discretionary co-investment partnerships to increase its capacity for larger deals.
- The new fund follows Claret’s €297 million Fund III, which closed in 2022 and backed companies including Cytora, Endomag, Lyst, Tiqets, and Abivax. Several of these companies have since been acquired or listed publicly.
“It continues to be a true privilege to support the founders and entrepreneurs who are driving real innovation across Europe at a monumental time for both business and society. As equity markets remain more selective and founders look for ways to grow without unnecessary dilution, we expect demand for flexible, non-dilutive capital to keep accelerating – and Fund IV positions us to meet that demand at scale," explains Johan Kampe, Managing Partner at Claret Capital Partners.
- Claret will use the new capital to continue expanding across Europe, with its team already growing in Paris and plans to establish a presence in Berlin. The firm said it is seeing continued demand from companies seeking financing for expansion, acquisitions, and product development without significant equity dilution.
